Form 4: Enliven Therapeutics CFO Exercises Stock Options and Reports Change in Beneficial Ownership
SEC Form 4 Filing
Benjamin Hohl, CFO of Enliven Therapeutics, exercised stock options for 10,000 shares at $2.48 on March 4, 2025, and reported a resulting change in beneficial ownership.
Summary
- On March 4, 2025, Benjamin Hohl, the Chief Financial Officer of Enliven Therapeutics, Inc. (ELVN), executed a transaction involving stock options.
- Hohl exercised options to purchase 10,000 shares of common stock at a price of $2.48 per share.
- Following the transaction, Hohl directly owns 23,000 shares of common stock.
- Hohl also directly owns 132,806 derivative securities in the form of stock options.
- The stock options were originally for 262,120 shares and vest over time.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing regarding stock option exercises, and does not contain information that would significantly impact sentiment positively or negatively.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency to investors regarding the holdings of company insiders.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding executive compensation and ownership.
Key Dates
| Date | Description |
|---|---|
| 08/02/2022 | Initial vesting date for one-fourth of the stock options. |
| 03/04/2025 | Date of the stock option exercise. |
| 03/06/2025 | Date of the form signature. |
| 08/02/2031 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.